Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension
NCT02047630 · CHU de Quebec-Universite Laval · PHASE4 · terminated · last registry update 2017-07-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Problem with IP supply” | – | Registry record, CHU de Quebec-Universite Laval |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-07-24Results posted on the registry: Bausch & Lomb Incorporated, BOL-303259-X + Latanoprost (NCT01223378)
- 2018-07-12Results posted on the registry: Wills Eye, Xalatan + Travatan Z (NCT00798694)
- 2018-06-06Results posted on the registry: Bausch & Lomb Incorporated, Latanoprostene bunod (NCT01895972)
- 2018-05-15Also stopped (withdrawn): Stanford University, Prostaglandin Analog + Timolol (NCT01927406)
- 2018-05-09Phase 3 first posted: Glaukos Corporation, G2-TR intraocular implant containing travoprost + Sham surgery + active-comparator eye drops (NCT03519386)
- 2018-04-20Results posted on the registry: ForSight Vision5, Inc., Bimatoprost + Timolol 0.5% (NCT01915940)
- 2018-04-17Results posted on the registry: Aerie Pharmaceuticals, AR-13324 Ophthalmic Solution 0.01% + AR-13324 Ophthalmic Solution 0.02% (NCT01731002)
- 2018-02-15Results posted on the registry: Inotek Pharmaceuticals Corporation, trabodenoson 6.0% / latanoprost 0.005% QD + trabodenoson 3.0% / latanoprost 0.005% QD (NCT02829996)
- 2018-02-14Results posted on the registry: University of Nebraska, Latanoprost + Dorzolamide (NCT00572936)
- 2018-02-05Phase 3 first posted: Taejoon Pharmaceutical Co., Ltd., TJO-002 + Latanoprost (NCT03419975)
- 2018-01-19Also stopped (withdrawn): Johns Hopkins University, a drug against PTGFR (NCT03274323)
- 2017-09-15Phase 3 first posted: Aerie Pharmaceuticals, Netarsudil/Latanoprost 0.02%/0.005% + GANFORT® (NCT03284853)
- 2017-09-13Results posted on the registry: University of Michigan, Variation in eye pressure response to timolol and latanoprost treatment (NCT01677507)
- 2017-06-29Results posted on the registry: Brigham and Women's Hospital, Oxytocin Infusion + Oxytocin Bolus (NCT01549223)
- 2017-03-17Also stopped (terminated): Allergan, Bimatoprost (NCT02676310)
- 2017-03-16Also stopped (terminated): Massachusetts Eye and Ear Infirmary, Travoprost + Latanoprost (NCT01315574)
- 2017-02-03Results posted on the registry: Massachusetts Eye and Ear Infirmary, Travoprost + Latanoprost (NCT01315574)
- 2017-01-23Results posted on the registry: Laboratoires Thea, T2347 + Xalacom (NCT02278614)
- 2016-12-05Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117 + Latanoprost ophthalmic solution (NCT02981446)
- 2016-09-26Phase 3 first posted: Ocular Therapeutix, Inc., Travoprost (NCT02914509)
- 2016-08-08Results posted on the registry: Alcon Research, Beta-blocker monotherapy + Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (NCT02003391)
- 2016-07-28Results posted on the registry: Université de Montréal, placebo + travoprost (NCT01711177)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision